Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKbeta Action in a Fiber-Type Specific Manner.
Metformin is a widely used insulin-sensitizing drug, though its mechanisms are not fully understood. Metformin has been shown to activate AMPK in skeletal muscle; however, its effects on the inhibitor of kappaB kinasebeta (IKKbeta) in this same tissue are unknown. The aim of this study was to (1) determine the ability of metformin to attenuate IKKbeta action, (2) determine whether changes in AMPK activity are associated with changes in IKKbeta action in skeletal muscle, and (3) examine whether changes in AMPK and IKKbeta function are consistent with improved insulin signaling. Lean and obese male Zuckers received either vehicle or metformin by oral gavage daily for four weeks (four groups of eight). Proteins were measured in white gastrocnemius (WG), red gastrocnemius (RG), and soleus. AMPK phosphorylation increased (P < .05) in WG in both lean (57%) and obese (106%), and this was supported by an increase in phospho-ACC in WG. Further, metformin increased IkappaBalpha levels in both WG (150%) and RG (67%) of obese rats, indicative of reduced IKKbeta activity (P < .05), and was associated with reduced IRS1-pSer(307) (30%) in the WG of obese rats (P < .02). From these data we conclude that metformin treatment appears to exert an inhibitory influence on skeletal muscle IKKbeta activity, as evidenced by elevated IkappaBalpha levels and reduced IRS1-Ser(307) phosphorylation in a fiber-type specific manner.
Bikman
Benjamin T
BT
The Metabolic Institute for the Study of Diabetes and Obesity, East Carolina University, Greenville, NC 27834, USA.
Zheng
Donghai
D
Kane
Daniel A
DA
Anderson
Ethan J
EJ
Woodlief
Tracey L
TL
Price
Jesse W
JW
Dohm
G Lynis
GL
Neufer
P Darrell
PD
Cortright
Ronald N
RN
J Clin Invest. 2001 Aug;108(3):437-46
11489937
Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E726-32
12488242
Biochem Biophys Res Commun. 2004 May 28;318(2):372-80
15120611
Biochem Biophys Res Commun. 2009 Nov 13;389(2):211-6
19706288
J Clin Endocrinol Metab. 2001 Mar;86(3):1306-12
11238525
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E955-64
19208854
J Biol Chem. 2004 Oct 1;279(40):41294-301
15252018
JAMA. 2004 Mar 10;291(10):1238-45
15010446
Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S6-11
14704736
J Clin Endocrinol Metab. 2008 Dec;93(12):4656-63
18765510
J Neurosci. 2004 Jan 14;24(2):479-87
14724246
Nature. 2006 Dec 14;444(7121):860-7
17167474
Diabetes. 2004 Jul;53(7):1649-54
15220186
Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R233-40
16081881
Nat Med. 2005 Feb;11(2):183-90
15685173
Am J Physiol Cell Physiol. 2005 Oct;289(4):C794-801
15888549
Curr Med Chem. 2006;13(5):583-9
16515522
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1204-9
15504342
Nature. 1998 Nov 5;396(6706):77-80
9817203
J Clin Invest. 2000 Aug;106(4):473-81
10953022
Diabetes. 2002 Aug;51(8):2420-5
12145153
Ann N Y Acad Sci. 2002 Jun;967:146-57
12079844
Diabetes. 2004 Dec;53(12):3258-66
15561958
Am J Physiol Endocrinol Metab. 2006 Feb;290(2):E251-7
16118254
Diabetes. 2002 Jul;51(7):2005-11
12086926
Science. 2001 Aug 31;293(5535):1673-7
11533494
J Physiol. 2006 Dec 15;577(Pt 3):997-1007
17008371
Hypertension. 2006 Jun;47(6):1183-8
16636195
Circulation. 2004 Jan 27;109(3):433-8
14744958
Hepatology. 2009 May;49(5):1525-36
19296465
Diabetes. 2002 Jan;51(1):7-18
11756317
Diabetologia. 2009 Dec;52(12):2616-20
19809797
Am J Physiol. 1997 Dec;273(6):E1107-12
9435525
Biochem J. 2000 Jun 15;348 Pt 3:607-14
10839993
J Clin Invest. 2005 May;115(5):1111-9
15864338
Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E18-23
11739078
J Appl Physiol (1985). 2006 Dec;101(6):1685-92
16902066
Nat Med. 2005 Feb;11(2):191-8
15685170
Cell Metab. 2006 Dec;4(6):465-74
17141630